Primary diffuse large B-cell lymphoma of the breast: Looking at pathogenesis, clinical issues and therapeutic options

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2236-2244

  Aviv Dr , A ^a   Tadmor, T ^b,c   Polliack, A ^d  

^a HAEMEK MEDICAL CENTER   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Breast lymphoma; CNS prophylaxis; Combined modality therapy; Diffuse large B cell lymphoma; DLBCL; Primary breast lymphoma (PBL)

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PREDNISONE; RITUXIMAB; SEX HORMONE; VINCRISTINE;

B LYMPHOCYTE DIFFERENTIATION; BINDING AFFINITY; BREAST CANCER; BREAST LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; CELL HOMING; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DOSE DENSIFICATION; DRUG MECHANISM; GENE EXPRESSION PROFILING; GERMINAL CENTER; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

BREAST LYMPHOMA; CNS PROPHYLAXIS; COMBINED MODALITY THERAPY; DIFFUSE LARGE B-CELL LYMPHOMA; DLBCL; PRIMARY BREAST LYMPHOMA (PBL);

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84883410718     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt192     Document Type: Review

References (95)

1. Validire P, Capovilla M, Asselain B et al. Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol 2009; 84: 133-139.
2. Yhim HY, Kang HJ, Choi YH et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer 2010; 10: 321.
3. Ryan G, Martinelli G, Kuper-Hommel M et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008; 19: 233-241.
4. Talwalkar SS, Miranda RN, Valbuena JR et al. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol 2008; 32: 1299-1309.
5. Fruchart C, Denoux Y, Chasle J et al. High grade primary breast lymphoma: is it a different clinical entity?. Breast Cancer Res Treat 2005; 93: 191-198.
6. Bierman PJ VM, Armitage JO. Diffuse large B-cell lymphoma of the breast: a distinct entity?. Ann Oncol 2008; 19: 201-202.
7. Avenia N, Sanquinetti A, Cirocchi R et al. Primary breast lymphomas: a multicentric experience. World J Surg Oncol 2010; 8: 53-57.
8. Martinelli G, Ryan G, Seymour JF et al. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the international extranodal lymphoma study group. Ann Oncol 2009; 20: 1993-1999.
9. Guo HY ZX, Li J, Hu XC. Primary non-Hodgkin's lymphoma of the breast: eight-year follow-up experience. Int J Hematol 2008; 87: 491-497.
10. Sabate JM GA, Torrubia S, Camins A et al. Lymphoma of the breast: clinical and radiological features with pathologic correlation in 28 patients. Breast J 2002; 8: 294-304.
11. Arber DA SJ, Weiss LM, Rappaport H. Non-Hodgkin's lymphoma involving the breast. Am J Surg Pathol 1994; 18: 288-295.
12. Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer 1972; 29: 1705-1712.
13. Uesato M, Miyazawa Y, Gunji Y et al. Primary non-Hodgkin lymphoma of the breast: report of a case with special reference to 380 cases in the Japanese literature. Breast Cancer 2005; 12: 154-158.
14. Gholam D, Bibeau F, El Weshi A et al. Primary breast lymphoma. Leuk Lymphoma 2003; 44: 1173-1178.
15. Jennings WC BR, Murray SS, Howard CA et al. Primary breast lymphoma: the role of mastectomy and the importance of lymph node status. Ann Surg 2007; 245: 784-789.
16. Jeanneret-Sozzi W, Taghian A, Epelbaum R et al. Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer 2008; 8: 86-92.
17. Cao YB WS, Huang HQ, Xu GC et al. Primary breast lymphoma-a report of 27 cases with literature review. Chinese J Cancer 2007; 26: 89-89.
18. Lin YC TC, Wu JS, Huang CS et al. Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast-a review of 42 primary and secondary cases in Taiwanese patients. Leuk Lymphoma 2009; 50: 918-924.
19. Zucca E, Conconi A, Mughal TI et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20-27.
20. Pals ST, de Gorter DJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007; 110: 3102-3111.
21. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
22. Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
23. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
24. Yoshida S, Nakamura N, Sasaki Y et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 2005; 18: 398-405.
25. Aviles A, Neri N, Nambo MJ. The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast. Am J Clin Oncol 2012; 35: 126-129.
26. Niitsu N, Okamoto M, Nakamine H et al. Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma. Leuk Res 2008; 32: 1837-1841.
27. Yhim HY, Kim JS, Kang HJ et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer 2012; 131: 235-243.
28. Mouna B, Saber B, Tijani EH et al. Primary malignant non-Hodgkin's lymphoma of the breast: a study of seven cases and literature review. World J Surg Oncol 2012; 10: 151-156.
29. Rathod J, Taori K, Disawal A et al. A rare case of male primary breast lymphoma. J Breast Cancer 2011; 14: 333-336.
30. Duman BB, Sahin B, Guvenc B et al. Lymphoma of the breast in a male patient. Med Oncol 2011; 28(Suppl. 1): S490-493.
31. Mpallas G, Simatos G, Tasidou A et al. Primary breast lymphoma in a male patient. Breast 2004; 13: 436-438.
32. Ko ES, Seol H, Shin JH et al. Primary anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma of the breast in a male patient. Br J Radiol 2012; 85: e79-e82.
33. Meerkotter D, Rubin G, Joske F et al. Primary breast lymphoma: a rare entity. J Radiol Case Rep 2011; 5: 1-9.
34. Shim GJ, Gherman D, Kim HJ et al. Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol 2006; 208: 408-414.
35. Yakimchuk K, Iravani M, Hasni MS et al. Effect of ligand-activated estrogen receptor beta on lymphoma growth in vitro and in vivo. Leukemia 2011; 25: 1103-1110.
36. Singh MP, Sharma H, Singh SM. Prolactin promotes growth of a spontaneous T cell lymphoma: role of tumor and host derived cytokines. Cancer Invest 2006; 24: 601-610.
37. Bishop JD, Nien WL, Dauphinee SM et al. Prolactin activates mammalian targetof- rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. J Endocrinol 2006; 190: 307-312.
38. Hooghe R, Merchav S, Gaidano G et al. A role for growth hormone and prolactin in leukaemia and lymphoma?. Cell Mol Life Sci 1998; 54: 1095-1101.
39. Skibola CF, Bracci PM, Paynter RA et al. Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 2391-2401.
40. Ariad S, Lewis D, Cohen R et al. Breast lymphoma. A clinical and pathological review and 10-year treatment results. S Afr Med J 1995; 85: 85-89.
41. Hugh JC, Jackson FI, Hanson J et al. Primary breast lymphoma. An immunohistologic study of 20 new cases. Cancer 1990; 66: 2602-2611.
42. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
43. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
44. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
45. Zhao S, Zhang QY, Ma WJ et al. Analysis of 31 cases of primary breast lymphoma: the effect of nodal involvement and microvascular density. Clin Lymphoma Myeloma Leuk 2011; 11: 33-37.
46. Fukuhara S, Watanabe T, Munakata W et al. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. Eur J Haematol 2011; 87: 434-440.
47. Ganjoo K, Advani R, Mariappan MR et al. Non-Hodgkin lymphoma of the breast. Cancer 2007; 110: 25-30.
48. Julen O, Dellacasa I, Pelte MF et al. Primary breast lymphomas. Rare Tumors 2009; 1: e14.
49. Seker M, Bilici A, Ustaalioglu BO et al. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast. Arch Gynecol Obstet 2011; 284: 405-409.
50. Barista I, Baltali E, Tekuzman G et al. Primary breast lymphomas-a retrospective analysis of twelve cases. Acta Oncol 2000; 39: 135-139.
51. Giardini R, Piccolo C, Rilke F. Primary non-Hodgkin's lymphomas of the female breast. Cancer 1992; 69: 725-735.
52. Smith MR, Brustein S, Straus DJ. Localized non-Hodgkin's lymphoma of the breast. Cancer 1987; 59: 351-354.
53. Wong WW, Schild SE, Halyard MY et al. Primary non-Hodgkin lymphoma of the breast: the Mayo Clinic Experience. J Surg Oncol 2002; 80: 19-25. Discussion 26.
54. Park YH, Kim SH, Choi SJ et al. Primary malignant lymphoma of the breast: clinicopathological study of nine cases. Leuk Lymphoma 2004; 45: 327-330.
55. Ha CS, Dubey P, Goyal LK et al. Localized primary non-Hodgkin lymphoma of the breast. Am J Clin Oncol 1998; 21: 376-380.
56. Caon J, Wai ES, Hart J et al. Treatment and outcomes of primary breast lymphoma. Clin Breast Cancer 2012; 12: 412-419.
57. Salzberg MP MJ, Press OW, Habermann TM et al. Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. In American Society of Hematology Annual Meeting, Atlanta, GA 2012.
58. Yang WT, Lane DL, Le-Petross HT et al. Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology 2007; 245: 692-702.
59. Santra A, Kumar R, Reddy R et al. FDG PET-CT in the management of primary breast lymphoma. Clin Nucl Med 2009; 34: 848-853.
60. Yi JI, Chae BJ, Bae JS et al. Bilateral primary breast lymphoma. Chin Med J (Engl) 2010; 123: 1482-1484.
61. Suzuki Y, Tokuda Y, Okumura A et al. Three cases of malignant lymphoma of the breast. Jpn J Clin Oncol 2000; 30: 33-36.
62. Ryan GF, Roos DR, Seymour JF. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma 2006; 6: 337-341.
63. Project TIN-HsLPF. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
64. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
65. Sokolov T, Shimonov M, Blickstein D et al. Primary lymphoma of the breast: unusual presentation of breast cancer. Eur J Surg 2000; 166: 390-393.
66. Avilés A, Delgado S, Nambo MJ et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005; 69: 256-260.
67. Avilés A, Castaneda C, Neri N et al. Rituximab and dose dense chemotherapy in primary breast lymphoma. Haematologica 2007; 92: 1147-1148.
68. Joks M, Mysliwiec K, Lewandowski K. Primary breast lymphoma - a review of the literature and report of three cases. Arch Med Sci 2011; 7: 27-33.
69. Kuper-Hommel MJ, Snijder S, Janssen-Heijnen ML et al. Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews. Ann Hematol 2003; 82: 397-404.
70. Liu MT, Hsieh CY, Wang AY et al. Primary breast lymphoma: a pooled analysis of prognostic factors and survival in 93 cases. Ann Saudi Med 2005; 25: 288-293.
71. Villa D, Connors JM, Shenkier TN et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21: 1046-1052.
72. Guirguis HR, Cheung MC, Mahrous M et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 2012; 159: 39-49.
73. Schmitz N, Zeynalova S, Glass B et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012; 23: 1267-1273.
74. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009; 89: 577-583.
75. Reyes F, Lepage E, Ganem G et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-1205.
76. Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 787-792.
77. Horning SJ, Weller E, Kim K et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22: 3032-3038.
78. Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non- Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-26.
79. Persky DO, Unger JM, Spier CM et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008; 26: 2258-2263.
80. Ng AK, Mauch PM. Role of radiation therapy in localized aggressive lymphoma. J Clin Oncol 2007; 25: 757-759.
81. dos Santos LV, Lima JP, Lima CS et al. Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma?. A systematic review with meta-analysis. BMC Cancer 2012; 12: 288.
82. Domchek SM, Hecht JL, Fleming MD et al. Lymphomas of the breast: primary and secondary involvement. Cancer 2002; 94: 6-13.
83. Jinming X, Qi Z, Xiaoming Z et al. Primary non-Hodgkin's lymphoma of the breast: mammography, ultrasound, MRI and pathologic findings. Future Oncol 2012; 8: 105-109.
84. van Besien K, Gisselbrecht C, Pfreundschuh M et al. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma 2008; 49(Suppl. 1): 52-58.
85. Korfel A. Prevention of central nervous system relapses in diffuse large Bcell lymphoma: which patients and how?. Curr Opin Oncol 2011; 23: 436-440.
86. Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011; 12: 1258-1266.
87. Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?. Blood Rev 2012; 26: 97-106.
88. Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 2009; 36: S2-S16.
89. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20: 319-332.
90. Tomita N, Yokoyama M, Yamamoto W et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2012; 103: 245-251.
91. Feugier P, Virion JM, Tilly H et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15: 129-133.
92. Loughrey MB, Windrum P, Catherwood MA et al. WHO reclassification of breast lymphomas. J Clin Pathol 2004; 57: 1213-1214.
93. Brogi E, Harris NL. Lymphomas of the breast: pathology and clinical behavior. Semin Oncol 1999; 26: 357-364.
94. Hollender A, Kvaloy S, Nome O et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13: 1099-1107.
95. Cheung CW, Burton C, Smith P et al. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 2005; 131: 193-200.